Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 24 | 2024 | 835 | 4.820 |
Why?
|
| Sexually Transmitted Diseases | 9 | 2024 | 97 | 4.670 |
Why?
|
| Sexual and Gender Minorities | 15 | 2024 | 205 | 3.700 |
Why?
|
| Pre-Exposure Prophylaxis | 13 | 2024 | 145 | 3.430 |
Why?
|
| Syphilis | 5 | 2024 | 33 | 2.000 |
Why?
|
| Homosexuality, Male | 15 | 2024 | 299 | 1.850 |
Why?
|
| Smallpox Vaccine | 2 | 2023 | 12 | 1.740 |
Why?
|
| Sexual Behavior | 5 | 2024 | 309 | 1.320 |
Why?
|
| Sexual Partners | 3 | 2024 | 100 | 1.140 |
Why?
|
| Vaccinia virus | 2 | 2023 | 19 | 1.100 |
Why?
|
| Sexual Health | 2 | 2024 | 17 | 1.080 |
Why?
|
| Viral Vaccines | 2 | 2023 | 44 | 1.060 |
Why?
|
| Family Practice | 1 | 2024 | 82 | 0.920 |
Why?
|
| Psychiatry | 1 | 2024 | 82 | 0.880 |
Why?
|
| Mental Health Services | 1 | 2023 | 57 | 0.870 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 64 | 0.840 |
Why?
|
| Vaccines | 1 | 2023 | 83 | 0.820 |
Why?
|
| Immunocompromised Host | 1 | 2023 | 142 | 0.810 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 463 | 0.740 |
Why?
|
| Anti-HIV Agents | 4 | 2024 | 155 | 0.730 |
Why?
|
| Mental Disorders | 1 | 2024 | 412 | 0.720 |
Why?
|
| Antiviral Agents | 2 | 2023 | 475 | 0.710 |
Why?
|
| Respiratory System | 1 | 2020 | 116 | 0.680 |
Why?
|
| Coinfection | 4 | 2024 | 61 | 0.630 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 304 | 0.620 |
Why?
|
| Humans | 42 | 2024 | 89063 | 0.610 |
Why?
|
| Community Health Centers | 1 | 2019 | 115 | 0.610 |
Why?
|
| Male | 25 | 2024 | 42251 | 0.540 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 319 | 0.530 |
Why?
|
| Monkeypox virus | 3 | 2023 | 6 | 0.490 |
Why?
|
| Adult | 15 | 2024 | 26507 | 0.490 |
Why?
|
| Internship and Residency | 1 | 2024 | 1041 | 0.490 |
Why?
|
| Gonorrhea | 2 | 2024 | 22 | 0.440 |
Why?
|
| Chlamydia Infections | 2 | 2024 | 30 | 0.440 |
Why?
|
| United States | 7 | 2024 | 6955 | 0.420 |
Why?
|
| Vaccination | 3 | 2023 | 273 | 0.420 |
Why?
|
| Students, Medical | 3 | 2023 | 418 | 0.420 |
Why?
|
| Adolescent | 7 | 2024 | 9237 | 0.400 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 1706 | 0.380 |
Why?
|
| Retrospective Studies | 10 | 2024 | 9003 | 0.360 |
Why?
|
| Middle Aged | 10 | 2024 | 25863 | 0.330 |
Why?
|
| Female | 17 | 2024 | 46011 | 0.320 |
Why?
|
| Young Adult | 5 | 2024 | 6288 | 0.310 |
Why?
|
| Pandemics | 4 | 2022 | 771 | 0.300 |
Why?
|
| Betacoronavirus | 2 | 2020 | 261 | 0.290 |
Why?
|
| Mass Screening | 3 | 2024 | 636 | 0.240 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2024 | 24 | 0.240 |
Why?
|
| Community Participation | 1 | 2024 | 38 | 0.240 |
Why?
|
| Hospitals, Urban | 1 | 2024 | 60 | 0.230 |
Why?
|
| Self-Examination | 1 | 2023 | 5 | 0.230 |
Why?
|
| Cell Phone | 1 | 2023 | 38 | 0.220 |
Why?
|
| Students, Pharmacy | 1 | 2023 | 1 | 0.220 |
Why?
|
| Anus Neoplasms | 1 | 2023 | 36 | 0.220 |
Why?
|
| Outpatients | 1 | 2023 | 100 | 0.220 |
Why?
|
| Papillomavirus Infections | 2 | 2024 | 261 | 0.220 |
Why?
|
| Vaccinia | 1 | 2022 | 3 | 0.220 |
Why?
|
| Ambulatory Care Facilities | 1 | 2024 | 111 | 0.220 |
Why?
|
| Anti-Retroviral Agents | 1 | 2023 | 31 | 0.210 |
Why?
|
| Crowdsourcing | 1 | 2022 | 12 | 0.210 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2023 | 80 | 0.210 |
Why?
|
| Mycoplasma genitalium | 1 | 2022 | 3 | 0.210 |
Why?
|
| Mobile Applications | 1 | 2023 | 68 | 0.210 |
Why?
|
| Mycoplasma Infections | 1 | 2022 | 9 | 0.210 |
Why?
|
| HIV-1 | 1 | 2023 | 166 | 0.210 |
Why?
|
| Papillomavirus Vaccines | 1 | 2023 | 58 | 0.200 |
Why?
|
| Transgender Persons | 1 | 2024 | 105 | 0.200 |
Why?
|
| Qualitative Research | 1 | 2023 | 291 | 0.200 |
Why?
|
| Incidence | 3 | 2023 | 1592 | 0.200 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 521 | 0.190 |
Why?
|
| Anxiety | 1 | 2023 | 308 | 0.190 |
Why?
|
| Prosthesis-Related Infections | 1 | 2021 | 60 | 0.190 |
Why?
|
| Risk Factors | 2 | 2023 | 5466 | 0.180 |
Why?
|
| Pacemaker, Artificial | 1 | 2021 | 94 | 0.180 |
Why?
|
| Racism | 1 | 2022 | 89 | 0.180 |
Why?
|
| Substance-Related Disorders | 1 | 2024 | 414 | 0.170 |
Why?
|
| Device Removal | 1 | 2021 | 167 | 0.170 |
Why?
|
| Reagins | 1 | 2019 | 1 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2023 | 295 | 0.170 |
Why?
|
| Defibrillators, Implantable | 1 | 2021 | 142 | 0.170 |
Why?
|
| Boston | 1 | 2019 | 36 | 0.170 |
Why?
|
| Telemedicine | 1 | 2022 | 185 | 0.170 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 2612 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2024 | 599 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 434 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 887 | 0.160 |
Why?
|
| Prevalence | 1 | 2021 | 1240 | 0.140 |
Why?
|
| Recurrence | 1 | 2019 | 1140 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 786 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2022 | 1043 | 0.120 |
Why?
|
| HIV | 2 | 2023 | 48 | 0.110 |
Why?
|
| Disease Outbreaks | 2 | 2023 | 154 | 0.100 |
Why?
|
| Bias | 2 | 2023 | 131 | 0.100 |
Why?
|
| Gender Identity | 2 | 2022 | 53 | 0.100 |
Why?
|
| China | 2 | 2022 | 233 | 0.100 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2023 | 67 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2023 | 865 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 833 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2023 | 2476 | 0.070 |
Why?
|
| District of Columbia | 1 | 2023 | 20 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2023 | 4273 | 0.060 |
Why?
|
| Physical Examination | 1 | 2024 | 148 | 0.050 |
Why?
|
| Pyridones | 1 | 2023 | 55 | 0.050 |
Why?
|
| Unsafe Sex | 1 | 2023 | 45 | 0.050 |
Why?
|
| Chlamydia trachomatis | 1 | 2022 | 15 | 0.050 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2022 | 17 | 0.050 |
Why?
|
| Condoms | 1 | 2022 | 38 | 0.050 |
Why?
|
| Viral Load | 1 | 2023 | 145 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2023 | 334 | 0.050 |
Why?
|
| Bisexuality | 1 | 2022 | 32 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 27 | 0.050 |
Why?
|
| Alanine | 1 | 2021 | 83 | 0.050 |
Why?
|
| Health Status | 1 | 2023 | 370 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2023 | 779 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2022 | 138 | 0.050 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 10 | 0.050 |
Why?
|
| Azithromycin | 1 | 2020 | 13 | 0.050 |
Why?
|
| Cephalosporins | 1 | 2020 | 24 | 0.040 |
Why?
|
| Machine Learning | 1 | 2022 | 257 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2020 | 43 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2022 | 386 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 257 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 73 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 442 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 531 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 1710 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 410 | 0.040 |
Why?
|
| Decision Making | 1 | 2021 | 665 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1423 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 876 | 0.030 |
Why?
|
| Child | 1 | 2020 | 7149 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2020 | 8203 | 0.020 |
Why?
|
| Aged | 1 | 2021 | 19077 | 0.010 |
Why?
|